Curing of Chloroquine-Resistant Malaria with Clindamycin

Peter G. KremsnerLandesinstitut fur Tropenmedizin, International Research Laboratory of the Albert-Schweitzer-Hospital, Department of Infectious Diseases, Internal Medicine I, University of Vienna, Berlin, Germany

Search for other papers by Peter G. Kremsner in
Current site
Google Scholar
PubMed
Close
,
Stefan WinklerLandesinstitut fur Tropenmedizin, International Research Laboratory of the Albert-Schweitzer-Hospital, Department of Infectious Diseases, Internal Medicine I, University of Vienna, Berlin, Germany

Search for other papers by Stefan Winkler in
Current site
Google Scholar
PubMed
Close
,
Christian BrandtsLandesinstitut fur Tropenmedizin, International Research Laboratory of the Albert-Schweitzer-Hospital, Department of Infectious Diseases, Internal Medicine I, University of Vienna, Berlin, Germany

Search for other papers by Christian Brandts in
Current site
Google Scholar
PubMed
Close
,
Wolfgang GraningerLandesinstitut fur Tropenmedizin, International Research Laboratory of the Albert-Schweitzer-Hospital, Department of Infectious Diseases, Internal Medicine I, University of Vienna, Berlin, Germany

Search for other papers by Wolfgang Graninger in
Current site
Google Scholar
PubMed
Close
, and
Ulrich BienzleLandesinstitut fur Tropenmedizin, International Research Laboratory of the Albert-Schweitzer-Hospital, Department of Infectious Diseases, Internal Medicine I, University of Vienna, Berlin, Germany

Search for other papers by Ulrich Bienzle in
Current site
Google Scholar
PubMed
Close
Restricted access

A randomized comparative trial for treating adult patients with Plasmodium falciparum malaria was performed in Lambarene, Gabon. Forty-two patients received chloroquine (25 mg/kg for 48 hr) and 38 patients received clindamycin (5 mg/kg twice a day, for five days). Chloroquine treatment cured 15 patients (36%). Twenty patients (48%) showed recrudescent malaria by day 28 of follow-up (RI resistance) and seven patients (17%) showed persistent parasitemia after chloroquine treatment (RII/III resistance). In contrast, clindamycin treatment cured 37 of 38 patients (97%) and only one (3%) showed a recrudescence by day 28 (P < 0.001). Although the parasite clearance time was significantly longer after clindamycin treatment (median five days, range 3–6) than after chloroquine treatment (median four days, range 2–8) (P < 0.01), no differences were seen in the duration of symptoms after chemotherapy. In both treatment groups, no severe side effects occurred. Clindamycin can be used as a safe alternative to achieve radical cure in semi-immune adult patients with chloroquine-resistant P. falciparum malaria in Central Africa.

Save